SIGLEC1 is a biomarker of disease activity and indicates extraglandular manifestation in primary Sjögren's syndrome.
SIGLEC1 is a biomarker of disease activity and indicates extraglandular manifestation in primary Sjögren's syndrome.
复制标题
DOI：
10.1136/rmdopen-2016-000292
复制
发表时间：
2016
期刊：
影响因子：
6.2
通讯作者：
Dörner T
中科院分区：
文献类型：
--
作者：
Rose T;Szelinski F;Lisney A;Reiter K;Fleischer SJ;Burmester GR;Radbruch A;Hiepe F;Grützkau A;Biesen R;Dörner T
评价原发性干燥综合征（pSS）患者干扰素（IFN）生物标志物唾液酸结合IG样凝集素1（SIGLEC 1，CD 169）和IFN-γ诱导蛋白-10（IP-10）的表达。纳入了31例符合美国-欧洲pSS标准的患者。通过EULAR干燥综合征疾病活动指数（ESSDAI）获得疾病活动性。使用流式细胞术分析单核细胞上的SIGLEC 1表达。使用Bioplex人细胞因子27-plex试剂盒测定IP-10浓度。采用斯皮尔曼秩和检验（SRT）进行相关性分析，采用曼-惠特尼U检验（MWU）检验腺体和腺体外表现之间的差异。在64.5%的pSS患者中，通过SIGLEC 1表达的上调和78.9%的pSS患者中IP-10血清水平的升高检测到激活的IFN系统。在随后的分析中，发现SIGLEC 1表达在具有腺外表现的患者中（16/16，100%）比仅具有腺体受累的患者（4/15，27%）更频繁地上调。SIGLEC 1表达可以显著区分这两种疾病亚组（p=0.0001，MWU），腺外疾病的阳性预测值（PPV）为80%。此外，表达与疾病活动性相关（p=0.005，r=0.54，SRT）。血清IP-10水平既没有显着差异之间的腺体和腺外疾病，也与ESSDAI。我们的研究结果表明，增加SIGLEC 1表达的特点是患者全身参与和高疾病活动。因此，SIGLEC 1的测定可能对pSS的亚群定义、危险分层和鉴别治疗考虑有价值。
To evaluate the interferon (IFN) biomarkers sialic acid binding Ig like lectin 1 (SIGLEC1, CD169) and IFN-γ-inducible protein-10 (IP-10) in patients with primary Sjögren's syndrome (pSS). 31 patients fulfilling the American-European criteria for pSS were included. Disease activity was obtained by EULAR Sjögren's syndrome disease activity index (ESSDAI). SIGLEC1 expression on monocytes was analysed using flow cytometry. IP-10 concentrations were determined using Bioplex human Cytokine 27-plex kit. Spearman rank test (SRT) was used for correlation analysis and Mann-Whitney U (MWU) to test for differences between glandular and extraglandular manifestations. An activated IFN system was detected by an upregulation of SIGLEC1 expression in 64.5% and by elevated serum level of IP-10 in 78.9% of our patients with pSS. In a subsequent analysis SIGLEC1 expression was found to be upregulated more frequently in patients with extraglandular manifestations (16/16, 100%) compared to patients with exclusively glandular involvement (4/15, 27%). SIGLEC1 expression could significantly discriminate between these two disease subgroups (p=0.0001, MWU) with a positive predictive value (PPV) of 80% for extraglandular disease. Moreover, the expression correlated with disease activity (p=0.005, r=0.54, SRT). Serum IP-10 levels neither differed significantly between glandular and extraglandular disease nor correlated with ESSDAI. Our results indicate that increased SIGLEC1 expression characterises patients with systemic involvement and high disease activity. Therefore, SIGLEC1 determination might be of value for subset definition, risk stratification and differential therapeutic considerations in pSS.